TP53 and cancer: These intriguing, though preliminary, observations suggest that cancer cells might either remove an inhibitory epigenetic marker present in normal cells or provide a co-activator for p53 absent in normal cells to activate the expression of PHLDB3 as another negative feedback regulator of this tumour suppressor for their growth advantage.